Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
447.50
-21.74 (-4.63%)
At close: Dec 18, 2024, 4:00 PM
393.50
-54.00 (-12.07%)
Pre-market: Dec 19, 2024, 7:41 AM EST
Vertex Pharmaceuticals Employees
Vertex Pharmaceuticals had 5,400 employees as of December 31, 2023. The number of employees increased by 600 or 12.50% compared to the previous year.
Employees
5,400
Change (1Y)
600
Growth (1Y)
12.50%
Revenue / Employee
$1,967,741
Profits / Employee
-$88,852
Market Cap
115.24B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 5,400 | 600 | 12.50% |
Dec 31, 2022 | 4,800 | 900 | 23.08% |
Dec 31, 2021 | 3,900 | 500 | 14.71% |
Dec 31, 2020 | 3,400 | 400 | 13.33% |
Dec 31, 2019 | 3,000 | 500 | 20.00% |
Dec 31, 2018 | 2,500 | 200 | 8.70% |
Dec 31, 2017 | 2,300 | 150 | 6.98% |
Dec 31, 2016 | 2,150 | 200 | 10.26% |
Dec 31, 2015 | 1,950 | 120 | 6.56% |
Dec 31, 2014 | 1,830 | 30 | 1.67% |
Dec 31, 2013 | 1,800 | -400 | -18.18% |
Dec 31, 2012 | 2,200 | 200 | 10.00% |
Dec 31, 2011 | 2,000 | 309 | 18.27% |
Dec 31, 2010 | 1,691 | 259 | 18.09% |
Dec 31, 2009 | 1,432 | 99 | 7.43% |
Dec 31, 2008 | 1,333 | 183 | 15.91% |
Dec 31, 2007 | 1,150 | 188 | 19.54% |
Dec 31, 2006 | 962 | 149 | 18.33% |
Dec 31, 2005 | 813 | 77 | 10.46% |
Dec 31, 2004 | 736 | 12 | 1.66% |
Dec 31, 2003 | 724 | -256 | -26.12% |
Dec 31, 2002 | 980 | -20 | -2.00% |
Dec 31, 2001 | 1,000 | 545 | 119.78% |
Dec 31, 2000 | 455 | 102 | 28.90% |
Dec 31, 1999 | 353 | 13 | 3.82% |
Dec 31, 1998 | 340 | 120 | 54.55% |
Dec 31, 1997 | 220 | 42 | 23.60% |
Dec 31, 1996 | 178 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Elevance Health | 104,900 |
Medtronic | 95,000 |
Pfizer | 88,000 |
Sanofi | 86,088 |
Danaher | 63,000 |
Boston Scientific | 48,000 |
Bristol-Myers Squibb Company | 34,100 |
Amgen | 26,700 |
VRTX News
- 7 days ago - Vertex Pharmaceuticals: Progress Check Suggests Stock Remains A Solid Buy - Seeking Alpha
- 9 days ago - Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock - Benzinga
- 10 days ago - Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update - Business Wire
- 19 days ago - Undercovered Dozen: Arqit Quantum, CleanSpark, Sezzle, STAG Industrial + - Seeking Alpha
- 23 days ago - Vertex Pharma: Why I Am Buying This Dip - Seeking Alpha
- 4 weeks ago - Buy Signal Flashing For Struggling Biotech - Forbes
- 4 weeks ago - Vertex Pharmaceuticals Incorporated (VRTX) Presents at Stifel 2024 Healthcare Conference (Transcript) - Seeking Alpha
- 4 weeks ago - Vertex Pharmaceuticals Incorporated (VRTX) Guggenheim Inaugural Healthcare Innovation Conference (Transcript) - Seeking Alpha